Cancer

Cover image for Vol. 122 Issue 15

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.649

ISI Journal Citation Reports © Ranking: 2015: 26/213 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 108
  1. Original Articles

    1. Discipline

      Survivorship
      You have full text access to this OnlineOpen article
      Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

      Jeanne S. Mandelblatt, Jonathan D. Clapp, Gheorghe Luta, Leigh Anne Faul, Michelle D. Tallarico, Trina D. McClendon, Jessica A. Whitley, Ling Cai, Tim A. Ahles, Robert A. Stern, Paul B. Jacobsen, Brent J. Small, Brandelyn N. Pitcher, Estrella Dura-Fernandis, Hyman B. Muss, Arti Hurria, Harvey J. Cohen and Claudine Isaacs

      Version of Record online: 22 JUL 2016 | DOI: 10.1002/cncr.30208

      • image
      • image

      Among older survivors of breast cancer who were followed for up to 7 years, approximately 42% reported maintaining high cognitive function, but receipt of chemotherapy (with or without hormonal therapy) appeared to double the odds of being in the group that reported accelerated cognitive decline (vs maintaining high function), compared with receiving hormonal treatment alone. Further research is needed to determine factors that place some older survivors at risk of experiencing cognitive decline.

    2. Clinical Trials
      The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial

      Charles W. Drescher, J. David Beatty, Robert Resta, M. Robyn Andersen, Kate Watabayashi, Jason Thorpe, Sarah Hawley, Hannah Purkey, Jessica Chubak, Nancy Hanson, Diana S. M. Buist and Nicole Urban

      Version of Record online: 22 JUL 2016 | DOI: 10.1002/cncr.30190

      • image
      • image

      Results from a randomized controlled trial confirm that routine referral of women who are at high risk for ovarian cancer to genetic counseling promotes genetic testing and risk-reduction surgery. These findings motivate action to design and implement efficient strategies to ensure that high-risk women are identified and offered access to currently available and recommended care.

    3. Translational Research
      Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men

      Aubrey R. Turner, Brian R. Lane, Dan Rogers, Isaac Lipkus, Kathryn Weaver, Suzanne C. Danhauer, Zheng Zhang, Fang-Chi Hsu, Sabrina L. Noyes, Tamara Adams, Helga Toriello, Thomas Monroe, Trudy McKanna, Tracey Young, Ryan Rodarmer, Richard J. Kahnoski, Mouafak Tourojman, A. Karim Kader, S. Lilly Zheng, William Baer and Jianfeng Xu

      Version of Record online: 19 JUL 2016 | DOI: 10.1002/cncr.30162

      • image
      • image
      • image

      This prospective trial shows that the provision of individual genetic risk scores for prostate cancer does not lead to significant increases in anxiety or in the use of prostate-specific antigen screening. Instead, genetic risk scores lead to the targeted use of prostate-specific antigen screening among higher risk men, and this may improve prostate-specific antigen screening performance.

    4. Disease Site

      Head and Neck Disease
      Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy

      Jian Ji Pan, Wai Tong Ng, Jing Feng Zong, Sarah W. M. Lee, Horace C. W. Choi, Lucy L. K. Chan, Shao Jun Lin, Qiao Juan Guo, Henry C. K. Sze, Yun Bin Chen, You Ping Xiao, Wai Kuen Kan, Brian O'Sullivan, Wei Xu, Quynh Thu Le, Christine M. Glastonbury, A. Dimitrios Colevas, Randal S. Weber, William Lydiatt, Jatin P. Shah and Anne W. M. Lee

      Version of Record online: 19 JUL 2016 | DOI: 10.1002/cncr.30198

      • image
      • image
      • image
      • image

      A nomogram incorporating the TNM stage group, age, gross primary tumor volume, and lactate dehydrogenase level significantly improves prognostic power in comparison with the TNM stage group alone. More personalized treatment decisions can be achieved with this refinement of risk stratification for individual patients with nasopharyngeal cancer.

    5. Hematologic Malignancies
      A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma

      Ajai Chari, Myo Htut, Jeffrey A. Zonder, Joseph W. Fay, Andrzej J. Jakubowiak, Joan B. Levy, Kenneth Lau, Steven M. Burt, Brian J. Tunquist, Brandi W. Hilder, Selena A. Rush, Duncan H. Walker, Mieke Ptaszynski and Jonathan L. Kaufman

      Version of Record online: 19 JUL 2016 | DOI: 10.1002/cncr.30174

      • image
      • image
      • image

      The current study reports on the results of a phase 1, multicenter, dose-escalation study of filanesib in combination with bortezomib, with or without dexamethasone, in patients with recurrent/refractory multiple myeloma. The combination appears to be well tolerated and has demonstrated durable activity in patients with recurrent/refractory myeloma.

    6. Discipline

      Disparities Research
      National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?

      Brandon A. Mahal, Yu-Wei Chen, Vinayak Muralidhar, Amandeep R. Mahal, Toni K. Choueiri, Karen E. Hoffman, Jim C. Hu, Christopher J. Sweeney, James B. Yu, Felix Y. Feng, Simon P. Kim, Clair J. Beard, Neil E. Martin, Quoc-Dien Trinh and Paul L. Nguyen

      Version of Record online: 19 JUL 2016 | DOI: 10.1002/cncr.30205

      • image
      • image
      • image

      Compared with white or privately insured patients, black, Hispanic, and uninsured patients are less likely to receive definitive therapy at both community and academic cancer centers; and, among patients who receive definitive therapy, black, Hispanic, and uninsured patients are more likely to experience treatment delays at both community and academic centers. Making community centers conform to academic center standards may not necessarily reduce treatment disparities.

  2. Review Articles

    1. Chemotherapy for soft tissue sarcoma

      Ravin Ratan and Shreyaskumar R. Patel

      Version of Record online: 19 JUL 2016 | DOI: 10.1002/cncr.30191

      Since the initial description of the activity of doxorubicin, several additional agents have been brought to bear in the treatment of soft tissue sarcomas. These drugs represent incremental rather than radical progress, although they constitute important and much needed treatment options for patients with these rare tumors.

  3. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

      Marcela G. del Carmen, Jeff G. Supko, Nora K. Horick, J. Alejandro Rauh-Hain, Rachel M. Clark, Susana M. Campos, Carolyn N. Krasner, Tina Atkinson and Michael J. Birrer

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/cncr.30196

      • image
      • image
      • image

      In this phase 1 and 2 trial, the appropriate dose of carboplatin-pralatrexate is identified in patients with recurrent, platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer. Most patients respond to the carboplatin-pralatrexate combination, and the regimen is well tolerated and effective in this population.

    2. Discipline

      Complementary Medicine
      Storage and disposal of medical cannabis among patients with cancer: Assessing the risk of diversion and unintentional digestion

      Sharon R. Sznitman, Victoria Goldberg, Hedva Sheinman-Yuffe, Ezequiel Flechter and Gil Bar-Sela

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/cncr.30185

      The results of the current study demonstrate high rates of suboptimal storage practices of medical cannabis as well as a lack of information given to patients and caregivers regarding the proper storage and disposal of medical cannabis. The findings herein indicate that oncologists and other health care providers have an important, yet unfilled, role to play in educating patients and caregivers of the importance of storing and disposing of medical cannabis in a safe manner.

  4. Correspondence

    1. Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base

      Adam S. Garden, Clifton D. Fuller, David I. Rosenthal, William N. William Jr, Gary B. Gunn, Beth M. Beadle, Faye M. Johnson, William H. Morrison, Jack Phan, Steven J. Frank, Merrill S. Kies and Erich M. Sturgis

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/cncr.30193

  5. Original Articles

    1. Disease Site

      Head and Neck Disease
      Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)

      Vasu Divi, Jonathan Harris, Paul M. Harari, Jay S. Cooper, Jonathan McHugh, Diana Bell, Erich M. Sturgis, Anthony J. Cmelak, Mohan Suntharalingam, David Raben, Harold Kim, Sharon A. Spencer, George E. Laramore, Andy Trotti, Robert L. Foote, Christopher Schultz, Wade L. Thorstad, Qiang (Ed) Zhang, Quynh Thu Le and F. Christopher Holsinger

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/cncr.30204

      • image
      • image
      • image
      • image
      • image

      The removal and evaluation of 18 or more lymph nodes are associated with improved overall survival for patients with node-positive mucosal head and neck cancer. This threshold should be further evaluated as a potential measure of quality in neck dissections.

    2. Discipline

      Outcomes Research
      A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas

      Schelomo Marmor, Erin E. Burke, Beth A. Virnig, Eric H. Jensen and Todd M. Tuttle

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/cncr.30199

      • image
      • image

      In the current study, survival rates after either surgery or chemotherapy alone are compared among elderly patients with pancreatic cancer. For the entire patient cohort, surgical treatment appears to be associated with improved survival rates, but the absolute benefit of surgery appears minimal for certain groups of patients (those aged ≥80 years and those with lymph node metastases).

    3. Disease Site

      Gastrointestinal Disease
      A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings

      Shannon M. Christy, Stacy N. Davis, Kimberly R. Williams, Xiuhua Zhao, Swapomthi K. Govindaraju, Gwendolyn P. Quinn, Susan T. Vadaparampil, Hui-Yi Lin, Steven K. Sutton, Richard R. Roethzeim, David Shibata, Cathy D. Meade and Clement K. Gwede

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/cncr.30207

      • image

      Providing fecal immunochemical test kits and educational print materials to black individuals in community settings results in high rates of colorectal cancer screening. The results also identify subgroups of participants who are less likely to return a fecal immunochemical test kit.

    4. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer

      Leigh Casadaban, Garth Rauscher, Mebea Aklilu, Dana Villenes, Sally Freels and Ajay V. Maker

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/cncr.30181

      • image
      • image
      • image

      In what to the authors' knowledge is the largest group of patients with stage II colon cancer evaluated to date, improved overall survival was found to be associated with adjuvant chemotherapy regardless of treatment regimen, patient age, or high-risk pathologic risk features.

    5. Breast Disease
      Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study

      Jean-Marc Ferrero, Anne-Claire Hardy-Bessard, Olivier Capitain, Alain Lortholary, Bruno Salles, Philippe Follana, Robert Herve, Mathilde Deblock, Jérôme Dauba, Mustapha Atlassi and Rémy Largillier

      Version of Record online: 14 JUL 2016 | DOI: 10.1002/cncr.30170

      • image
      • image
      • image

      The single-arm A-TaXel study evaluated a triplet regimen of paclitaxel, capecitabine, and bevacizumab followed by maintenance therapy with capecitabine plus bevacizumab as first-line treatment among patients with triple-negative metastatic breast cancer. The regimen demonstrated high activity (an objective response rate of 77%, a median progression-free survival of 7.6 months, and a median overall survival of 19.2 months) and manageable safety in this difficult-to-treat population.

    6. Discipline

      Symptom Control and Palliative Care
      Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials

      Goldy C. George, Eucharia C. Iwuanyanwu, Karen O. Anderson, Alizeh Yusuf, Ralph G. Zinner, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Aung Naing, Siqing Fu, Filip Janku, Vivek Subbiah, Charles S. Cleeland, Tito R. Mendoza and David S. Hong

      Version of Record online: 14 JUL 2016 | DOI: 10.1002/cncr.30182

      • image

      Poor sleep quality is a significant problem (64%) for patients with advanced cancer in a clinic for early-phase clinical trials. Compared with good sleepers, poor sleepers have higher levels of fatigue, symptom burden, and mood disturbance. Sleep quality should be routinely assessed in early-phase clinical trials.

    7. Disease Site

      Hematologic Malignancies
      Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation

      Sameh Gaballa, Isabell Ge, Riad El Fakih, Jonathan E. Brammer, Piyanuch Kongtim, Ciprian Tomuleasa, Sa A. Wang, Dean Lee, Demetrios Petropoulos, Kai Cao, Gabriela Rondon, Julianne Chen, Aimee Hammerstrom, Lindsey Lombardi, Gheath Alatrash, Martin Korbling, Betul Oran, Partow Kebriaei, Sairah Ahmed, Nina Shah, Katayoun Rezvani, David Marin, Qaiser Bashir, Amin Alousi, Yago Nieto, Muzaffar Qazilbash, Chitra Hosing, Uday Popat, Elizabeth J. Shpall, Issa Khouri, Richard E. Champlin and Stefan O. Ciurea

      Version of Record online: 12 JUL 2016 | DOI: 10.1002/cncr.30180

      • image
      • image
      • image

      After transplantation, combined cyclophosphamide, tacrolimus, and mycophenolate is an effective graft-versus-host disease prophylaxis strategy for patients with advanced hematologic malignancies who undergo not only haploidentical donor but also human leukocyte antigen-mismatched unrelated donor (9/10 MUD) transplantation. The results from this study support melphalan-based conditioning as an effective regimen for a broad range of hematologic malignancies.

    8. Discipline

      Pediatric Oncology
      Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation

      Ajay K. Nooka, Madhusmita Behera, Sagar Lonial, Margie D. Dixon, Suresh S. Ramalingam and Rebecca D. Pentz

      Version of Record online: 12 JUL 2016 | DOI: 10.1002/cncr.30090

      With the exception of Hispanic children, enrollment in Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 trials is mostly representative across racial, ethnic, age, and sex categories..

    9. Epidemiology
      The temporal relationship between diabetes and cancer: A population-based study

      Iliana C. Lega, Andrew S. Wilton, Peter C. Austin, Hadas D. Fischer, Jeffrey A. Johnson and Lorraine L. Lipscombe

      Version of Record online: 11 JUL 2016 | DOI: 10.1002/cncr.30095

      • image
      • image

      Diabetes is associated with an increased risk of several cancers. However, the risk appears to be limited to the time periods before and immediately after a diabetes diagnosis. The highest risk period was observed within the first 3 months after a diabetes diagnosis, suggesting a partial role of detection bias in the apparent relationship between diabetes and cancer.

  6. Correspondence

  7. Original Articles

    1. Discipline

      Disparities Research
      Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer

      Daniel J. Kagedan, Liza Abraham, Nik Goyert, Qing Li, Lawrence F. Paszat, Alexander Kiss, Craig C. Earle, Nicole Mittmann and Natalie G. Coburn

      Version of Record online: 8 JUL 2016 | DOI: 10.1002/cncr.30148

      • image

      Sociodemographic marginalization exerts its influence early in the pancreatic cancer care continuum. Patients with increasing levels of residential instability and material deprivation, as well as those living in rural areas and neighborhoods with lower median incomes, are less likely to undergo surgical resection of pancreatic cancer.

    2. Psychosocial Oncology
      Comorbid symptoms of emotional distress in adult survivors of childhood cancer

      Norma Mammone D'Agostino, Kim Edelstein, Nan Zhang, Christopher J. Recklitis, Tara M. Brinkman, Deokumar Srivastava, Wendy M. Leisenring, Leslie L. Robison, Gregory T. Armstrong and Kevin R. Krull

      Version of Record online: 8 JUL 2016 | DOI: 10.1002/cncr.30171

      This study examines emotional distress profiles in childhood cancer survivors. Four unique patterns, including a group with comorbid symptoms requiring different intervention approaches, are identified.

    3. Disease Site

      Melanoma
      Downstream consequences of melanoma screening in a community practice setting: First results

      Martin A. Weinstock, Laura K. Ferris, Melissa I. Saul, Alan C. Geller, Patricia M. Risica, Julia A. Siegel, Francis X. Solano and John M. Kirkwood

      Version of Record online: 8 JUL 2016 | DOI: 10.1002/cncr.30177

      The risks of melanoma screening after training primary care providers with the INFORMED (INternet course FOR Melanoma Early Detection) program appear minimal, because screening a large population appears to lead to increased diagnoses of melanoma but has little impact on either surgeries on the skin or dermatology visits. This provides some reassurance that such efforts can be conducted without major adverse consequences, at least as measured by these parameters, and therefore should be considered for more widespread use.See also pages.

  8. Editorial

    1. Lack of harms from community-based melanoma screening by primary care providers

      Clara Curiel-Lewandrowski and Susan M. Swetter

      Version of Record online: 8 JUL 2016 | DOI: 10.1002/cncr.30194

      Skin cancer screening by primary care physicians results in the increased diagnosis of melanomas without affecting the number of referrals to specialists and surgical procedures. The identification of nonmelanoma skin cancers as part of melanoma screening efforts should not be considered a deleterious effect. See also pages.

  9. Original Articles

    1. Discipline

      Survivorship
      Patient-centered support in the survivorship care transition: Outcomes from the Patient-Owned Survivorship Care Plan Intervention

      Elizabeth A. Kvale, Chao-Hui Sylvia Huang, Karen M. Meneses, Wendy Demark-Wahnefried, Sejong Bae, Casey B. Azuero, Gabrielle B. Rocque, Kerri S. Bevis and Christine S. Ritchie

      Version of Record online: 7 JUL 2016 | DOI: 10.1002/cncr.30136

      • image
      • image
      • image

      The POSTCARE survivorship care transition intervention demonstrates a positive impact on quality of life and depressive symptom burden. An emphasis on patient engagement and self-management may shift survivorship care planning outcomes.

    2. Disease Site

      Head and Neck Disease
      Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations

      Simion I. Chiosea, Lester D. R. Thompson, Ilan Weinreb, Julie E. Bauman, Alyssa M. Mahaffey, Caitlyn Miller, Robert L. Ferris and William E. Gooding

      Version of Record online: 5 JUL 2016 | DOI: 10.1002/cncr.30179

      • image
      • image
      • image

      On the basis of morphologic and molecular evidence (PLAG1 and HMGA2 status) of pleomorphic adenoma, 4 subsets of salivary duct carcinoma are identified that have distinct distributions of potentially targetable genetic alterations. Next-generation sequencing reveals that de novo salivary duct carcinomas are characterized by combined HRAS/PIK3CA mutations and an absence of ERBB2 copy number gain.

    3. Discipline

      Outcomes Research
      Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population

      Bruce L. Jacobs, Samia H. Lopa, Jonathan G. Yabes, Joel B. Nelson, Amber E. Barnato and Howard B. Degenholtz

      Version of Record online: 5 JUL 2016 | DOI: 10.1002/cncr.30184

      • image
      • image

      Functional status is associated with treatment choice for men with prostate cancer, even after adjustments for tumor grade and disease risk. Future research should examine whether this is due to physician recommendations, patient preferences, or a combination.

    4. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer

      Namrata Vijayvergia, Tianyu Li, Yu-Ning Wong, Michael J. Hall, Steven J. Cohen and Efrat Dotan

      Version of Record online: 5 JUL 2016 | DOI: 10.1002/cncr.30077

      • image
      • image

      The treatment of metastatic colorectal cancer has changed substantially in the last 2 decades, but to the authors' knowledge, the effect of age and comorbidities on chemotherapy use has not been well studied to date. The current study is a retrospective analysis of the effect of age and comorbidities on chemotherapy use in commercially insured patients with metastatic colorectal cancer.

    5. Survivorship
      Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008

      Nicholas Donin, Christopher Filson, Alexandra Drakaki, Hung-Jui Tan, Alex Castillo, Lorna Kwan, Mark Litwin and Karim Chamie

      Version of Record online: 5 JUL 2016 | DOI: 10.1002/cncr.30164

      • image
      • image
      • image
      • image

      Nearly 1 in 12 cancer survivors develops a second primary malignancy, most commonly among survivors of bladder cancer. Greater than one-half of patients with 2 primary cancers die of their second cancer.

    6. Radiation Oncology
      You have full text access to this OnlineOpen article
      Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy

      Goro Kasuya, Hitoshi Ishikawa, Hiroshi Tsuji, Takuma Nomiya, Hirokazu Makishima, Tadashi Kamada, Koichiro Akakura, Hiroyoshi Suzuki, Jun Shimazaki, Yasuo Haruyama, Gen Kobashi, Hirohiko Tsujii and for the Working Group for Genitourinary Tumors

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30050

      Two prospective phase 2 studies involving 324 high-risk prostate cancer patients treated with carbon-ion radiotherapy have revealed that the presence of biochemical recurrence is an independent predictive factor for overall mortality (hazard ratio, 2.82; 95% confidence interval, 1.57-5.08; P = .001) in patients with high-risk prostate cancer after carbon-ion radiotherapy according to a multivariate analysis.

    7. Disease Site

      Hematologic Malignancies
      Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496)

      Stefan K. Barta, Hailun Li, Howard S. Hochster, Fangxin Hong, Edie Weller, Randy D. Gascoyne, Thomas M. Habermann, Leo I. Gordon, Natalia Colocci, Elizabeth M. Bengtson, Sandra J. Horning and Brad S. Kahl

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30137

      • image
      • image
      • image

      Long-term follow-up from the E1496 study shows that maintenance rituximab results in a long-lasting progression-free survival benefit without significant toxicities for patients with indolent lymphomas. However, overall survival does not differ between patients on maintenance rituximab and patients on observation.

    8. Discipline

      Disparities Research
      Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina

      Ashley T. Freeman, Anne-Marie Meyer, Andrew B. Smitherman, Lei Zhou, Ethan M. Basch, Thomas C. Shea and William A. Wood

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30139

      • image

      Survival among patients with acute myeloid leukemia in North Carolina varies according to geographic region, and these survival disparities may be attributed to differences in the local health care infrastructure. Further examination of local practice and referral patterns may inform strategies to improve outcomes for patients with acute myeloid leukemia in North Carolina.

    9. Disease Site

      Hematologic Malignancies
      Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma

      Dai Chihara, Jason R. Westin, Yasuhiro Oki, Mohamed A. Ahmed, Bryan Do, Luis E. Fayad, Fredrick B. Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Hun J. Lee, Francesco Turturro, Felipe Samaniego, Sattva S. Neelapu, M. Alma Rodriguez, Nathan H. Fowler, Michael Wang, Richard E. Davis and Loretta J. Nastoupil

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30173

      • image
      • image
      • image

      Very elderly fit patients (age ≥ 80 years) have survival outcomes similar to those of younger patients with standard-dose anthracycline-based regimens. Patient education and close monitoring with sufficient supportive therapy during treatment are imperative for preventing treatment-related mortality.

  10. Correspondence

    1. Reply to breast cancer risk by the extent and type of atypical hyperplasia

      Laura C. Collins, Stuart J. Schnitt and Rulla M. Tamimi

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30149

  11. Original Articles

    1. Discipline

      Radiation Oncology
      Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database

      Kyle Wang, Nathan C. Sheets, Ramsankar Basak and Ronald C. Chen

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30154

      • image

      Among men who receive postprostatectomy radiotherapy within 1 year of undergoing surgery, Surveillance, Epidemiology, and End Results (SEER) data appear to underascertain the receipt of radiotherapy in 44% of patients. SEER data alone should not be used to examine patterns of secondary treatment in patients with prostate cancer.

    2. Disease Site

      Breast Disease
      Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women

      Amy C. Degnim, William D. Dupont, Derek C. Radisky, Robert A. Vierkant, Ryan D. Frank, Marlene H. Frost, Stacey J. Winham, Melinda E. Sanders, Jeffrey R. Smith, David L. Page, Tanya L. Hoskin, Celine M. Vachon, Karthik Ghosh, Tina J. Hieken, Lori A. Denison, Jodi M. Carter, Lynn C. Hartmann and Daniel W. Visscher

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30153

      • image

      In the Mayo Clinic and Nashville cohort studies of benign breast disease, the number of foci of atypical hyperplasia stratifies the long-term breast cancer risk for both the atypical ductal hyperplasia subtype and the atypical lobular hyperplasia subtype. See also pages 000-000 and 000-000.

  12. Correspondence

    1. Breast cancer risk by the extent and type of atypical hyperplasia

      Amy C. Degnim, Daniel W. Visscher, Derek C. Radisky, Marlene H. Frost, Robert A. Vierkant, Ryan D. Frank, Stacey J. Winham, Celine M. Vachon, William D. Dupont and Lynn C. Hartmann

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30151

  13. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Feasibility and diagnostic accuracy of the Patient-Reported Outcomes Measurement Information System (PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care

      Yvonne W. Leung, Catherine Brown, Andrea Perez Cosio, Aditi Dobriyal, Noor Malik, Vivien Pat, Margaret Irwin, Pascale Tomasini, Geoffrey Liu and Doris Howell

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30134

      • image
      • image
      • image
      • image

      The feasibility and diagnostic accuracy of the Patient-Reported Outcomes Measurement Information System Computerized Adaptive Testing for fatigue and sleep-disturbance items are assessed in an observational study and compared with legacy measures. The findings support the feasibility and diagnostic accuracy of the system and its potential for use in routine ambulatory cancer care.

    2. Epidemiology
      Childhood leukemia incidence in California: High and rising in the Hispanic population

      Brenda M. Giddings, Todd P. Whitehead, Catherine Metayer and Mark D. Miller

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30129

      Compared with non-Hispanic white children, Hispanic children in California appear to have a significantly higher incidence of acute lymphoblastic leukemia whereas African American and Asian/Pacific Islander children have a significantly lower incidence. Moreover, the incidence of acute lymphoblastic and acute myeloid leukemia appear to be significantly increasing among Hispanic children, predominantly among females, but not among non-Hispanic white children.

    3. Disease Site

      Soft Tissue and Bone Sarcoma
      Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA

      Masanori Hayashi, David Chu, Christian F. Meyer, Nicolas J. Llosa, Gregory McCarty, Carol D. Morris, Adam S. Levin, Jean-Paul Wolinsky, Catherine M. Albert, Diana A. Steppan, Ben Ho Park and David M. Loeb

      Version of Record online: 28 JUN 2016 | DOI: 10.1002/cncr.30144

      • image
      • image
      • image
      • image
      • image

      By identifying the specific EWS-ETS breakpoint in patients with Ewing sarcoma, the authors were able to design a personalized plasma tumor DNA detection system using droplet digital polymerase chain reaction. The number of detected breakpoint fragments correlated with tumor burden and metastatic disease recurrence in an animal model, and was piloted in 3 patients, demonstrating strong translational potential.

    4. Discipline

      Outcomes Research
      Vulnerable elders survey and socioeconomic status predict functional decline and death among older women with newly diagnosed nonmetastatic breast cancer

      Cynthia Owusu, Seunghee Margevicius, Mark Schluchter, Siran M. Koroukian, Kathryn H. Schmitz and Nathan A. Berger

      Version of Record online: 27 JUN 2016 | DOI: 10.1002/cncr.30046

      • image
      • image
      • image

      Among older women with newly diagnosed nonmetastatic breast cancer, functional decline within 12 months of breast cancer treatment is highly prevalent, and women of lower educational status are disproportionately affected. The Vulnerable Elders Survey is a useful tool for the early identification of women at risk for functional decline.

    5. Disease Site

      Genitourinary Disease
      Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era

      Tracy L. Rose, Allison M. Deal, Bhavani Krishnan, Matthew E. Nielsen, Angela B. Smith, William Y. Kim and Matthew I. Milowsky

      Version of Record online: 24 JUN 2016 | DOI: 10.1002/cncr.30146

      • image
      • image

      Both African American and Caucasian patients with advanced renal cell carcinoma have had a significant improvement in survival since the advent of targeted therapy. However, African American patients maintain a survival disadvantage compared with Caucasian patients independent of treatment received.

  14. Editorial

    1. Human immunodeficiency virus lymphomas in the era of antiretrovirals: Is it finally time to change the discussion?

      Clifford J. Gunthel and Mary Jo Lechowicz

      Version of Record online: 23 JUN 2016 | DOI: 10.1002/cncr.30110

      Currently, clinicians involved in the treatment of and research regarding lymphoma may want to look toward achieving the goal of a dual cure of human immunodeficiency virus and cancer in patients with lymphoma. In addition, the difficult issues of health care disparities, disease prevention, and long-term survivorship need to be addressed in this population.

  15. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base

      Adam J. Olszewski, Jaleh Fallah and Jorge J. Castillo

      Version of Record online: 23 JUN 2016 | DOI: 10.1002/cncr.30112

      • image
      • image
      • image

      Most patients with newly diagnosed human immunodeficiency virus-associated lymphoma in the United States are black or Hispanic. The risk of not receiving chemotherapy is associated with sociodemographic characteristics and is significantly lower in higher volume or academic/research facilities. See also pages 000-000.

    2. Discipline

      Clinical Trials
      Telehealth system: A randomized controlled trial evaluating the impact of an internet-based exercise intervention on quality of life, pain, muscle strength, and fatigue in breast cancer survivors

      Noelia Galiano-Castillo, Irene Cantarero-Villanueva, Carolina Fernández-Lao, Angélica Ariza-García, Lourdes Díaz-Rodríguez, Rosario Del-Moral-Ávila and Manuel Arroyo-Morales

      Version of Record online: 22 JUN 2016 | DOI: 10.1002/cncr.30172

      • image
      • image
      • image
      • image

      This is one of the most extensive randomized controlled trials to report effect sizes for telerehabilitation in breast cancer survivors using an adequate follow-up period. This nonface-to-face approach could help the growing number of cancer survivors who use information and communications technology as a delivery method.

  16. Erratum

    1. You have free access to this content
      Erratum

      Version of Record online: 22 JUN 2016 | DOI: 10.1002/cncr.30178

  17. Review Articles

    1. Adult brainstem gliomas

      Sylvia C. Eisele and David A. Reardon

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/cncr.29920

      • image
      • image
      • image
      • image

      Brainstem gliomas typically affect children and are uncommon among adults. Emerging molecular genetic data support the development of promising biologically based, novel treatment strategies for these challenging tumors.

  18. Erratum

    1. You have free access to this content
  19. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer

      Katelin A. Mirkin, Erin K. Greenleaf, Christopher S. Hollenbeak and Joyce Wong

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/cncr.30163

      • image
      • image
      • image

      The earlier initiation of adjuvant chemotherapy does not significantly impact long-term survival in patients with resected pancreatic cancer. Because adjuvant chemotherapy confers a survival benefit, delayed chemotherapy should be offered when appropriate.

    2. Discipline

      Radiation Oncology
      Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer

      Bree R. Eaton, Renjian Jiang, Mylin A. Torres, Shannon T. Kahn, Karen Godette, Timothy L. Lash and Kevin C. Ward

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/cncr.30142

      • image
      • image
      • image

      In this SEER-Medicare analysis of 3432 women aged ≥ 70 years with T1-2N0 estrogen receptor-negative breast cancer, the use of adjuvant radiotherapy after breast-conserving therapy was associated with a significantly reduced incidence of mastectomy and breast cancer death. However, among the subgroup of women aged ≥80 years or with T1N0 tumors the absolute difference in the incidence of mastectomy with or without receipt of radiotherapy was small.

    3. Disease Site

      Breast Disease
      Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: Rate of upgrade to carcinoma at excision

      Fresia Pareja, Adriana D. Corben, Sandra B. Brennan, Melissa P. Murray, Zenica L. Bowser, Kiran Jakate, Christopher Sebastiano, Monica Morrow, Elizabeth A. Morris and Edi Brogi

      Version of Record online: 17 JUN 2016 | DOI: 10.1002/cncr.30118

      • image
      • image

      The rate at which intraductal papillomas without atypia constituting the most serious finding in radiologic-pathologic concordant core-needle biopsy specimens are upgraded to carcinoma at surgical excision is low. Radiologic follow-up is appropriate management for these patients.

    4. Hematologic Malignancies
      Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

      Abhinav Deol, Salyka Sengsayadeth, Kwang Woo Ahn, Hai-Lin Wang, Mahmoud Aljurf, Joseph Harry Antin, Minoo Battiwalla, Martin Bornhauser, Jean-Yves Cahn, Bruce Camitta, Yi-Bin Chen, Corey S. Cutler, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Yoshihiro Inamoto, Madan Jagasia, Rammurti Kamble, John Koreth, Hillard M. Lazarus, Jane Liesveld, Mark R. Litzow, David I. Marks, Taiga Nishihori, Richard F. Olsson, Ran Reshef, Jacob M. Rowe, Ayman A. Saad, Mitchell Sabloff, Harry C. Schouten, Thomas C. Shea, Robert J. Soiffer, Geoffrey L. Uy, Edmond K. Waller, Peter H. Wiernik, Baldeep Wirk, Ann E. Woolfrey, Donald Bunjes, Steven Devine, Marcos de Lima, Brenda M. Sandmaier, Dan Weisdorf, Hanna Jean Khoury and Wael Saber

      Version of Record online: 17 JUN 2016 | DOI: 10.1002/cncr.30140

      • image
      • image

      FMS-like tyrosine kinase 3 (FLT3) mutation status does not have an impact on overall survival after allogeneic hematopoietic stem cell transplantation. Pre-emptive strategies to reduce relapse need to be investigated in patients who have FLT3 mutations to further improve outcomes after hematopoietic stem cell transplantation.

    5. Breast Disease
      A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial

      Jan C. Drooger, Harm van Tinteren, Steffen M. de Groot, Albert J. ten Tije, Hiltje de Graaf, Johanneke E. A. Portielje, Agnes Jager, Aafke Honkoop, Sabine C. Linn, Judith R. Kroep, Frans L. G. Erdkamp, Paul Hamberg, Alex L. T. Imholz, Quirine C. van Rossum-Schornagel, Joan B. Heijns, A. Elise van Leeuwen-Stok and Stefan Sleijfer

      Version of Record online: 17 JUN 2016 | DOI: 10.1002/cncr.30141

      • image
      • image
      • image

      Results from this study suggest that bevacizumab adds clinically relevant antitumor activity to certain trastuzumab-based regimens in human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer. In particular, a sequential approach with bevacizumab and trastuzumab, delaying the start of cytotoxic chemotherapy, is worth further exploration in studies incorporating newer HER2-targeted agents and endocrine therapy in patients with hormone receptor-positive disease.

    6. Discipline

      Clinical Trials
      Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)

      Florence Lerebours, Sofia Rivera, Marie-Ange Mouret-Reynier, Severine Alran, Laurence Venat-Bouvet, Pierre Kerbrat, Remy Salmon, Veronique Becette, Céline Bourgier, Pascal Cherel, Véronique Boussion, Corinne Balleyguier, Fabienne Thibault, Sandrine Lavau-Denes, Jean-Marc Nabholz, Brigitte Sigal, Martine Trassard, Marie-Christine Mathieu, Anne-Laure Martin, Jerome Lemonnier and Emmanuelle Mouret-Fourme

      Version of Record online: 17 JUN 2016 | DOI: 10.1002/cncr.30143

      • image
      • image
      • image
      • image

      Neoadjuvant anastrozole and fulvestrant are efficient and well tolerated in postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. The Preoperative Endocrine Prognostic Index status is significantly predictive of relapse-free survival.

    7. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study

      Sung Hee Lim, Jong-Mu Sun, Yoon-La Choi, Hye Ryun Kim, Soomin Ahn, Ji Yun Lee, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Joo Hang Kim, Byoung Chul Cho and Myung-Ju Ahn

      Version of Record online: 17 JUN 2016 | DOI: 10.1002/cncr.30135

      • image
      • image
      • image

      Dovitinib demonstrates an objective response rate of 11.5% (95% confidence interval, 0.8%-23.8%) in patients with advanced squamous cell cancer of the lung whose tumors demonstrate fibroblast growth factor receptor 1 (FGFR1) amplification by fluorescence in situ hybridization assay. Further research to evaluate predictive biomarkers correlated with the efficacy of fibroblast growth factor receptor inhibitors are needed. See also pages 000-000.

  20. Editorial

    1. Missing the mark in FGFR1-amplified squamous cell cancer of the lung

      Paul K. Paik and Charles M. Rudin

      Version of Record online: 17 JUN 2016 | DOI: 10.1002/cncr.30131

      In contrast to targeted therapy development in lung adenocarcinoma, trials targeting fibroblast growth factor receptor 1 (FGFR1) in squamous cell lung cancers generally have been disappointing. Gene amplification or overexpression of this target may not be a sufficiently robust predictor of efficacy for FGFR1 inhibitors. See also pages 000-000.

  21. Review Articles

    1. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

      Sebastian Giebel, Anna Czyz, Oliver Ottmann, Frederic Baron, Eolia Brissot, Fabio Ciceri, Jan J. Cornelissen, Jordi Esteve, Norbert-Claude Gorin, Bipin Savani, Christoph Schmid, Mohamad Mohty and Arnon Nagler

      Version of Record online: 16 JUN 2016 | DOI: 10.1002/cncr.30130

      • image

      Tyrosine kinase inhibitor maintenance therapy after allogeneic hematopoietic stem cell transplantation has been demonstrated to reduce the risk of relapse of Philadelphia chromosome–positive acute lymphoblastic leukemia. This consensus paper, written on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, presents an overview of the use of tyrosine kinase inhibitors after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome–positive acute lymphoblastic leukemia and proposes recommendations regarding the choice of tyrosine kinase inhibitor, treatment timing, and dosage.

    2. Endometrial cancer: Not your grandmother's cancer

      Jessica N. McAlpine, Sarah M. Temkin and Helen J. Mackay

      Version of Record online: 16 JUN 2016 | DOI: 10.1002/cncr.30094

      • image
      • image

      An exciting new era of endometrial cancer research and clinical management has begun that incorporates biologically and clinically relevant genomic and clinicopathologic parameters. Continued collaborative research efforts and funding are essential if we are to advance our understanding of this disease and improve clinical outcomes.

  22. Original Articles

    1. Discipline

      Radiation Oncology
      Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation

      Cameron W. Swanick, Xiudong Lei, Simona F. Shaitelman, Pamela J. Schlembach, Elizabeth S. Bloom, Michelle C. Fingeret, Eric A. Strom, Welela Tereffe, Wendy A. Woodward, Michael C. Stauder, Tomas Dvorak, Alastair M. Thompson, Thomas A. Buchholz and Benjamin D. Smith

      Version of Record online: 15 JUN 2016 | DOI: 10.1002/cncr.30121

      • image
      • image
      • image

      In the current study, the authors assess longitudinal patient-reported outcomes and physician-rated cosmesis in a randomized trial of conventionally fractionated whole-breast irradiation plus boost versus hypofractionated whole-breast irradiation plus boost for the adjuvant treatment of patients with early-stage breast cancer. The treatment arm appears to have no significant effect on longitudinal outcomes, and patient-reported functional and pain outcomes improve with time.

    2. Disease Site

      Breast Disease
      Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies

      Jeffrey S. Ross, Laurie M. Gay, Kai Wang, Siraj M. Ali, Saranya Chumsri, Julia A. Elvin, Ron Bose, Jo-Anne Vergilio, James Suh, Roman Yelensky, Doron Lipson, Juliann Chmielecki, Stanley Waintraub, Brian Leyland-Jones, Vincent A. Miller and Philip J. Stephens

      Version of Record online: 10 JUN 2016 | DOI: 10.1002/cncr.30102

      • image
      • image

      Nonamplification ERBB2 mutations cannot be detected by standard-of-care immunohistochemistry or fluorescence in situ hybridization, although the presence of these alterations may predict response to human epidermal growth factor receptor 2-targeted therapy. In a series of 5605 metastatic breast cancers, 2.4% of all cases and 20% of cases with ERBB2 alterations were found to harbor nonamplification mutations, which represents a substantial patient population who may benefit from human epidermal growth factor receptor 2-targeted therapies.

  23. Correspondence

  24. Original Articles

    1. Discipline

      Radiation Oncology
      Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

      Jack M. Qian, James B. Yu, Harriet M. Kluger and Veronica L. S. Chiang

      Version of Record online: 10 JUN 2016 | DOI: 10.1002/cncr.30138

      • image
      • image
      • image

      For melanoma brain metastases, immune checkpoint therapy administered within 4 weeks of stereotactic radiosurgery is more effective than treatment separated by more than 4 weeks. In addition, anti–programmed cell death protein 1 therapy increases the lesional response to stereotactic radiosurgery in comparison with anti–cytotoxic T-lymphocyte-associated protein 4.

    2. Disparities Research
      Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma

      Justine M. Kahn, Theresa H.M. Keegan, Li Tao, Renata Abrahão, Archie Bleyer and Aaron D. Viny

      Version of Record online: 10 JUN 2016 | DOI: 10.1002/cncr.30089

      • image

      A retrospective analysis of 4 decades of Surveillance, Epidemiology, and End Results data show that although survival for children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma has improved, differences persist between black, white, and Hispanic children, adolescents, and young adults. Survival disparities between black and white children with acute lymphoblastic leukemia have been nearly eliminated.

  25. Correspondence

    1. Reply to smoking cessation for patients with cancer: “The Emperor's New Clothes”

      Apoorva T. Ramaswamy, Benjamin Toll, Anees B. Chagpar and Benjamin L. Judson

      Version of Record online: 10 JUN 2016 | DOI: 10.1002/cncr.30152

  26. Original Articles

    1. Discipline

      Survivorship
      Cigarette smoking, comorbidity, and general health among survivors of adolescent and young adult cancer

      Sapna Kaul, Sreenivas P. Veeranki, Ana M. Rodriguez and Yong-Fang Kuo

      Version of Record online: 10 JUN 2016 | DOI: 10.1002/cncr.30086

      Survivors of adolescent and young adult cancer are more likely to smoke cigarettes than a comparison group. Cigarette smoking among survivors is associated with comorbidity and poor or fair general health. The majority of survivors start smoking before diagnosis, and nearly 40% of current smokers report not having smoking-related discussions with health professionals in the previous year.

    2. Patterns and predictors of clustered risky health behaviors among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study

      E. Anne Lown, Nobuko Hijiya, Nan Zhang, Deo Kumar Srivastava, Wendy M. Leisenring, Paul C. Nathan, Sharon M. Castellino, Katie A. Devine, Kimberley Dilley, Kevin R. Krull, Kevin C. Oeffinger, Melissa M. Hudson, Gregory T. Armstrong, Leslie L. Robison and Kirsten K. Ness

      Version of Record online: 3 JUN 2016 | DOI: 10.1002/cncr.30106

      • image
      • image

      Herein, the authors identify 3 health behavior clusters among survivors of childhood cancer and their siblings. Psychological distress and economic and educational disadvantages should be considered when designing interventions to address risky health behaviors in this population.

  27. Review Articles

    1. You have free access to this content
      Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state-of-the-science review

      Jan T. Lowery, Dennis J. Ahnen, Paul C. Schroy III, Heather Hampel, Nancy Baxter, C. Richard Boland, Randall W. Burt, Lynn Butterly, Megan Doerr, Mary Doroshenk, W. Gregory Feero, Nora Henrikson, Uri Ladabaum, David Lieberman, Elizabeth G. McFarland, Susan K. Peterson, Martha Raymond, N. Jewel Samadder, Sapna Syngal, Thomas K. Weber, Ann G. Zauber and Robert Smith

      Version of Record online: 3 JUN 2016 | DOI: 10.1002/cncr.30080

      Persons with a family history of colorectal cancer or adenomas have an increased risk for colorectal cancer, yet they are not adequately screened according to consensus guidelines. The mitigation of barriers to screening through improved identification of these individuals, the education of providers and patients about risk and screening recommendations, the encouragement of family communication, and the implementation of practice-based interventions are needed to reduce the burden of colorectal cancer in these families. See also pages 000-000.

  28. Editorial

    1. You have free access to this content
      Family history matters

      Marie E. Wood

      Version of Record online: 3 JUN 2016 | DOI: 10.1002/cncr.30078

      Targeting individuals at increased risk for colon cancer will ensure that those most at risk for the disease will benefit; a family history is an easily identifiable risk factor for colon cancer. The review by Lowery et al. in this issue of Cancer highlights both the importance of taking a family history for identifying those at risk for colorectal cancer and the barriers to effectively using family history information to manage individuals at risk. See also pages 000-000.

  29. Original Articles

    1. Discipline

      Pediatric Oncology
      Genetic testing for the risk of developing late effects among survivors of childhood cancer: Consumer understanding, acceptance, and willingness to pay

      Gabrielle Georgiou, Claire E. Wakefield, Brittany C. McGill, Joanna E. Fardell, Christina Signorelli, Lucy Hanlon, Kathy Tucker, Andrea F. Patenaude and Richard J. Cohn

      Version of Record online: 3 JUN 2016 | DOI: 10.1002/cncr.30119

      • image
      • image

      Survivors of childhood cancer and their parents describe a positive interest in genetic testing for the risk of developing late effects. Perceived benefits appear to outweigh harms, and the majority of participants would be willing to pay, and wait, for such testing.

  30. Editorials

    1. Improving the patient experience in the delivery of high quality surgical care and health outcomes

      Simon P. Kim and Robert Abouassaly

      Version of Record online: 2 JUN 2016 | DOI: 10.1002/cncr.30076

      With passage of the Patient Protection and Affordable Care Act, the Centers for Medicare and Medicaid Services have placed a greater degree of emphasis on value for health care delivery by focusing on improving health outcomes and quality and lowering costs. In this issue of Cancer, Shirk et al examine the relationship between the patient-centered experience and hospital outcomes for patients undergoing radical prostatectomy, nephrectomy, and cystectomy for genitourinary malignancies. See also pages 000-000.

  31. Original Articles

    1. Discipline

      Outcomes Research
      Patient experience and quality of urologic cancer surgery in US hospitals

      Joseph D. Shirk, Hung-Jui Tan, Jim C. Hu, Christopher S. Saigal and Mark S. Litwin

      Version of Record online: 2 JUN 2016 | DOI: 10.1002/cncr.30081

      • image

      Patient experience is increasingly tied to reimbursement, but the correlation with surgical quality is unclear. In the current study, the authors demonstrate a limited association between patient experience and surgical outcomes for those individuals undergoing surgery for genitourinary cancer, suggesting that these domains remain separate when used to evaluate provider performance. See also pages 000-000.

    2. Cost-effectiveness of alternative colonoscopy surveillance strategies to mitigate metachronous colorectal cancer incidence

      Fatih Safa Erenay, Oguzhan Alagoz, Ritesh Banerjee, Adnan Said and Robert R. Cima

      Version of Record online: 1 JUN 2016 | DOI: 10.1002/cncr.30091

      • image
      • image
      • image

      This study identifies cost-effective alternative colonoscopy surveillance strategies by evaluating all clinically reasonable surveillance strategies with a computer-simulation model. The results illustrate that slightly increasing the surveillance intensity of the US guideline may significantly improve health outcomes while moderately increasing surveillance costs.

    3. Disease Site

      Gastrointestinal Disease
      Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma

      Jordan M. Cloyd, Christopher H. Crane, Eugene J. Koay, Prajnan Das, Sunil Krishnan, Laura Prakash, Rebecca A. Snyder, Gauri R. Varadhachary, Robert A. Wolff, Milind Javle, Rachna T. Shroff, David Fogelman, Michael Overman, Huamin Wang, Anirban Maitra, Jeffrey E. Lee, Jason B. Fleming and Matthew H. G. Katz

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30117

      • image

      In this single-institution review of patients undergoing preoperative therapy before pancreatoduodenectomy for pancreatic ductal adenocarcinoma, the administration of hypofractionated chemoradiation is associated with margin-negative resection rates, treatment effect, locoregional recurrence, and overall survival similar to those associated with standard fractionated chemoradiation. The use of either preoperative chemoradiation regimen is associated with improved locoregional control (but not overall survival) in comparison with systemic chemotherapy alone.

    4. Head and Neck Disease
      Comparative effectiveness of surgical and nonsurgical therapy for advanced laryngeal cancer

      Chun Chieh Lin, Stacey A. Fedewa, Kara K. Prickett, Kristin A. Higgins and Amy Y. Chen

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30122

      • image
      • image

      Complete chemoradiation (CRT) for advanced laryngeal cancer was found to have a similar survival benefit to that of surgery. However, a substantial percentage of patients who initiated CRT did not complete the course. Although CRT provides organ preservation, the benefits and trade-offs between the treatments and the importance of completing the full course of CRT should be fully discussed with patients.

    5. Breast Disease
      Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ

      Oyewale O. Shiyanbola, Brian L. Sprague, John M. Hampton, Kim Dittus, Ted A. James, Sally Herschorn, Ronald E. Gangnon, Donald L. Weaver and Amy Trentham-Dietz

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30105

      • image

      Recommended guidelines highlight a conservative approach to the management of ductal carcinoma in situ. According to data for women diagnosed with ductal carcinoma in situ in the National Cancer Data Base, the use of adjuvant radiation therapy after breast-conserving surgery has plateaued since 2007, and mastectomy, including reconstruction and removal of the contralateral breast, has increased with demographic variation. See also pages 000-000.

  32. Editorial

    1. Ductal carcinoma in situ: How much is too much?

      Keerthi Gogineni

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30107

      In this issue of Cancer, Shiyanbola et al describe changing trends in the treatment of ductal carcinoma in situ. Their findings reinforce the need for research into the natural history of ductal carcinoma in situ that may enable women with low-risk lesions to undergo less invasive treatment. See also pages 000-000.

  33. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

      Gevorg N. Tamamyan, Hagop M. Kantarjian, Jing Ning, Preetesh Jain, Koji Sasaki, Kenneth L. McClain, Carl E. Allen, Sherry A. Pierce, Jorge E. Cortes, Farhad Ravandi, Marina Y. Konopleva, Guillermo Garcia-Manero, Christopher B. Benton, Dai Chihara, Michael E. Rytting, Sa Wang, Waleed Abdelall, Sergej N. Konoplev and Naval G. Daver

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30084

      • image
      • image
      • image
      • image

      Malignancy-associated hemophagocytic lymphohistiocytosis (HLH) in adults is frequently associated with hematologic malignancies, and the outcomes are dismal. In this retrospective, single-institute study, the authors analyze the characteristics of 61 adult patients with pathologic evidence of hemophagocytosis and identified new variables that which may aid in the diagnosis of malignancy-associated HLH. The results also confirm the poor outcomes in patients with malignancy-associated HLH.

    2. Gastrointestinal Disease
      Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers

      Nishi Kothari, Jamie K. Teer, Andrea M. Abbott, Thejal Srikumar, Yonghong Zhang, Sean J. Yoder, Andrew S. Brohl, Richard D. Kim, Damon R. Reed and David Shibata

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30082

      • image
      • image
      • image

      The authors describe their original research involving exome sequencing of patients with colorectal cancer in which younger patients were compared with older patients. A unique genetic profile is identified for younger patients that may have implications on future screening and treatment paradigms for these patients.

    3. Hepatobiliary Disease
      Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases

      Georgios A. Margonis, Yuhree Kim, Kazunari Sasaki, Mario Samaha, Neda Amini and Timothy M. Pawlik

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30085

      • image
      • image
      • image
      • image

      Overall KRAS mutation is not associated with recurrence-free survival in patients who undergo resection of CRLM. However, KRAS codon 13 mutations are associated with a higher risk for overall extrahepatic recurrence and lung-specific recurrence.

    4. Gynecologic Oncology
      Accuracy of urinary human papillomavirus testing for the presence of cervical human papillomaviruses and higher grades of cervical intraepithelial neoplasia

      Chandrika J. Piyathilake, Suguna Badiga, Michelle M. Chambers, Ilene K. Brill, Roland Matthews and Edward E. Partridge

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30123

      • image
      • image
      • image

      The purpose of this study is to determine the accuracy of urinary human papillomavirus (HPV) testing for the presence of cervical HPVs and higher grade cervical intraepithelial lesions. The results demonstrate that urinary HPV testing provides highly satisfactory results for excluding the possibility of any cervical HPV infections, including HPV types not included in vaccines and cervical intraepithelial neoplasia lesions associated with any high-risk HPV, regardless of a woman's age, race, or excess body weight.

    5. Discipline

      Symptom Control and Palliative Care
      Helping parents live with the hole in their heart: The role of health care providers and institutions in the bereaved parents' grief journeys

      Jennifer M. Snaman, Erica C. Kaye, Carlos Torres, Deborah V. Gibson and Justin N. Baker

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30087

      Parents of children who die often experience significant psychosocial and health sequelae and may benefit from ongoing support and resources throughout their grief journey. In this article, bereaved parents identify the quintessential components of bereavement support that they believe should be provided by individual members of the medical team and by the institution as a whole.

  34. Correspondence

  35. Original Articles

    1. Discipline

      Disparities Research
      Racial and ethnic differences in patient navigation: Results from the Patient Navigation Research Program

      Naomi Y. Ko, Frederick R. Snyder, Peter C. Raich, Electra D. Paskett, Donald J. Dudley, Ji-Hyun Lee, Paul H. Levine and Karen M. Freund

      Version of Record online: 26 MAY 2016 | DOI: 10.1002/cncr.30109

      • image

      The current study explores whether patient navigation reduces racial and ethnic differences in the time to diagnostic resolution of a cancer screening abnormality. The study demonstrates that patient navigation significantly reduces the median time to diagnostic resolution in black participants, although the reduction does not appear to entirely eliminate disparities between this and other racial and ethnic groups.

    2. Disease Site

      Genitourinary Disease
      Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer

      Joshua A. Halpern, Art Sedrakyan, Wei-Chun Hsu, Jialin Mao, Timothy J. Daskivich, Paul L. Nguyen, Encouse B. Golden, Josephine Kang and Jim C. Hu

      Version of Record online: 25 MAY 2016 | DOI: 10.1002/cncr.30101

      • image
      • image

      The use of stereotactic body radiotherapy (SBRT) and proton beam therapy for the treatment of patients with localized prostate cancer in the United States has increased over time. Despite men of lower stage undergoing SBRT, SBRT appears to be associated with greater toxicity but lower health care costs compared with other radiotherapies.

    3. Breast Disease
      You have full text access to this OnlineOpen article
      An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy

      Christina M. Dieli-Conwright, Louise Wong, Sarah Waliany, Leslie Bernstein, Behrouz Salehian and Joanne E. Mortimer

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30104

      Patients with breast cancer who receive (neo)adjuvant chemotherapy experience an impaired metabolic presentation as noted by worsened components of metabolic syndrome, anthropometrics, and biomarkers of glucose metabolism. Lifestyle interventions such as diet and exercise may be preventive approaches for use during chemotherapy to reduce the onset of metabolic syndrome in patients with breast cancer.

    4. Gastrointestinal Disease
      Predicting advanced neoplasia at colonoscopy in a diverse population with the National Cancer Institute colorectal cancer risk-assessment tool

      Uri Ladabaum, Ashley Patel, Ajitha Mannalithara, Vandana Sundaram, Aya Mitani and Manisha Desai

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30096

      • image
      • image
      • image
      • image

      The National Cancer Institute colorectal cancer risk-assessment tool, which was designed to predict future colorectal cancer risk, displays modest discriminatory accuracy in predicting advanced neoplasia at screening colonoscopy in a diverse population. This tool may aid shared decision-making in clinical practice.

    5. Discipline

      Pediatric Oncology
      Parental preparedness for late effects and long-term quality of life in survivors of childhood cancer

      Katie A. Greenzang, Angel M. Cronin and Jennifer W. Mack

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30092

      • image
      • image

      The parents of children with cancer believe themselves to be prepared to manage their child's cancer treatment, but they feel less prepared for survivorship. High-quality communication with providers may help parents to feel more prepared for their child's life after cancer therapy.

    6. Diagnostic Imaging
      Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care

      Vaios Hatzoglou, Antonio M. Omuro, Sofia Haque, Yasmin Khakoo, Ian Ganly, Jung Hun Oh, Amita Shukla-Dave, Robin Fatovic, Joshua Gaal and Andrei I. Holodny

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30083

      • image
      • image

      Delivering the highest quality of cancer care is an important issue and must continue to be emphasized. Second-opinion interpretations of neuroimaging studies by subspecialized oncologic neuroradiologists reduce error and optimize the care of cancer patients.

    7. Radiation Oncology
      PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer

      Andrew J. McPartlin, Rachel Glicksman, Melania Pintilie, Debbie Tsuji, Gary Mok, Andrew Bayley, Peter Chung, Robert G. Bristow, Mary K. Gospodarowicz, Charles N. Catton, Michael Milosevic and Padraig R. Warde

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30093

      • image
      • image
      • image
      • image

      The PMH 9907 trial was a randomized study assessing the outcome of dose-escalated external-beam radiotherapy with or without 5 months neoadjuvant and concurrent bicalutamide 150 mg once daily for 252 patients with localized prostate cancer. After a median follow-up of 9.1 years, a nonsignificant 7% difference in the biochemical failure rate is reported in favor of combination therapy.

    8. Outcomes Research
      Early impact of Medicare accountable care organizations on cancer surgery outcomes

      Lindsey A. Herrel, Edward C. Norton, Scott R. Hawken, Zaojun Ye, Brent K. Hollenbeck and David C. Miller

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30111

      • image

      Early hospital participation in the accountable care organization program of the Medicare Shared Savings Program is not associated with greater reductions in adverse perioperative outcomes for patients undergoing a major cancer surgery in comparison with control hospitals. The longitudinal improvements in perioperative outcomes identified during the study interval may reflect the impact of concurrent policies more directly applicable to surgical patients.

    9. Disease Site

      Gastrointestinal Disease
      Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity

      Djenaba A. Joseph, Reinier G. S. Meester, Ann G. Zauber, Diane L. Manninen, Linda Winges, Fred B. Dong, Brandy Peaker and Marjolein van Ballegooijen

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30070

      • image
      • image
      • image

      There is sufficient colonoscopy capacity to screen 80% of the eligible US population with fecal immunochemical testing, colonoscopy, or a mix of tests.

    10. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

      Zachary S. Morris, Sandeep Saha, William J. Magnuson, Brett A. Morris, Jenna F. Borkenhagen, Alisa Ching, Gayle Hirose, Vanesa McMurry, David M. Francis, Paul M. Harari, Rick Chappell, Stuart Tsuji and Mark A. Ritter

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30079

      • image
      • image

      The incidental use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among rectal cancer patients receiving neoadjuvant radiotherapy is associated with an increased rate of pathological complete response. This finding is verified in a second independent database, and a multivariate aggregate analysis shows that the use of these medications is a strong predictor of a pathologic complete response.

    11. Hematologic Malignancies
      Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma

      Yago Nieto, Benigno C. Valdez, Peter F. Thall, Roy B. Jones, Wei Wei, Alan Myers, Chitra Hosing, Sairah Ahmed, Uday Popat, Elizabeth J. Shpall, Muzaffar Qazilbash, Alison Gulbis, Paolo Anderlini, Nina Shah, Qaiser Bashir, Amin Alousi, Yasuhiro Oki, Michelle Fanale, Bouthaina Dabaja, Chelsea Pinnix, Richard Champlin and Borje S. Andersson

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30100

      • image
      • image

      With the objective of developing more active high-dose chemotherapy for patients with refractory or high-risk relapsed lymphomas, infusional gemcitabine/busulfan/melphalan is combined with vorinostat and azacitidine (which enhanced antitumor activity in preclinical work). This clinical trial demonstrates that double epigenetic modulation of high-dose chemotherapy is safe and highly active in patients with refractory lymphomas.

  36. Review Articles

    1. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma

      Jens Jakob and Peter Hohenberger

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.29991

      • image
      • image
      • image

      Isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan is a highly effective regional treatment for locally advanced soft tissue sarcoma. This review critically discusses the indication for isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan.

  37. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States

      John Ha, Melissa Yan, Maria Aguilar, Taft Bhuket, Michele M. Tana, Benny Liu, Robert G. Gish and Robert J. Wong

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30103

      • image
      • image
      • image
      • image

      Asians have the highest incidence and prevalence of hepatocellular carcinoma (HCC) in the United States. Although non-Hispanic whites, blacks, and Hispanics all had increasing incidence of HCC from 2003 to 2011, Asians had a declining incidence and a shift from advanced HCC to earlier stage HCC as a result of improved HCC screening and surveillance efforts. See also pages 000-000.

VIEW

  1. 1 - 100
  2. 101 - 108

SEARCH

SEARCH BY CITATION